Hims & Hers and Tempus AI are transforming digital health in distinct ways, but which platform looks more compelling right ...

Following the acquisition of Paige in 2025, Tempus launches its new AI-powered, biomarker prediction solution for digital ...

Tempus AI's diagnostics segment shows strong pricing power, with Oncology ASP rising from $1,630 to over $2,200. Read why TEM ...

In smaller moves, ARK sold 2,631 shares of Kratos Defense and Security Solutions Inc (NASDAQ:KTOS) across three ETFs for $317,272, and purchased 7,175 shares of Kodiak AI Inc (KDK) through its ARKQ ...

ARK Invest bought $7.27M Netflix stock and sold $4.19M Beam Therapeutics on Jan 21, 2026. Full breakdown of Cathie Wood's ...

BIOMAKERS, a precision medicine and oncology intelligence company headquartered in San Francisco, today announced the closing of an additional $8 million. The financing marks a key inflection point as ...

On the selling side, ARK offloaded 135,193 shares of Beam Therapeutics Inc (NASDAQ:BEAM), with a total dollar value of $4,186,927. This sale was distributed between ARKK and ARKG ETFs, suggesting a ...

The global computer vision in healthcare market is projected to expand by USD 10.97 billion between 2025 and 2030, with an impressive CAGR of 31.1% during this period. This compre ...

Nancy Pelosi has never been a passive market spectator, and her latest portfolio moves show she is still willing to lean into ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on BillionToOne, Inc. Class A ( BLLN – Research Report) and Dexcom ( DXCM – Research Report ).

BIOMAKERS, a precision medicine and oncology intelligence company headquartered in San Francisco, today announced the closing ...

Avacta Therapeutics said on Wednesday that it has received clearance from the US Food and Drug Administration for the ...